Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Nov;68(5):932–938. doi: 10.1038/bjc.1993.457

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

R Danesi 1, S Del Bianchi 1, P Soldani 1, A Campagni 1, R V La Rocca 1, C E Myers 1, A Paparelli 1, M Del Tacca 1
PMCID: PMC1968736  PMID: 7692920

Abstract

The effects of suramin, an inhibitor of growth factor mitogenic activity, were evaluated on basic fibroblast growth factor (bFGF)-induced proliferation of bovine aortic endothelial cells and on angiogenesis in the chorioallantoic membrane (CAM) of chick embryos. The role of bFGF gene expression in endothelial cell growth was also investigated by using an antisense oligodeoxynucleotide to bFGF. The 4-fold increase in [3H]-thymidine uptake in endothelial cells in vitro upon stimulation with 10 ng ml-1 of bFGF was inhibited by suramin 300 micrograms ml-1. bFGF antisense oligomer (10 microM) reduced [3H]-thymidine incorporation in exponentially growing cells by 76%; this effect was reversed by bFGF 10 ng ml-1. In the CAM of chick embryos suramin 50 micrograms was a more potent inhibitor of angiogenesis than the combination of heparin 60 micrograms/hydrocortisone 50 micrograms; the mean value of the area with reduced vascularity was significantly larger in suramin-treated CAMs (2.4 cm2) than in heparin/hydrocortisone (0.6 cm2), while the reduction of vascular density was similar (- 35 and - 29% compared to controls, respectively), In conclusion, the effects of treatments with bFGF and bFGF antisense oligomer demonstrate that bFGF plays a relevant role in endothelial cell proliferation and may be the target of suramin since the drug is able to suppress basal and bFGF-induced endothelial cell growth; in addition to this, suramin is a more potent angiogenesis inhibitor in the CAM than the combination of heparin/hydrocortisone.

Full text

PDF
932

Images in this article

934Figure 1
on p.934
935Figure 4
on p.935

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham J. A., Mergia A., Whang J. L., Tumolo A., Friedman J., Hjerrild K. A., Gospodarowicz D., Fiddes J. C. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science. 1986 Aug 1;233(4763):545–548. doi: 10.1126/science.2425435. [DOI] [PubMed] [Google Scholar]
  2. Baldin V., Roman A. M., Bosc-Bierne I., Amalric F., Bouche G. Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J. 1990 May;9(5):1511–1517. doi: 10.1002/j.1460-2075.1990.tb08269.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Becker D., Meier C. B., Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. 1989 Dec 1;8(12):3685–3691. doi: 10.1002/j.1460-2075.1989.tb08543.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coffey R. J., Jr, Leof E. B., Shipley G. D., Moses H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987 Jul;132(1):143–148. doi: 10.1002/jcp.1041320120. [DOI] [PubMed] [Google Scholar]
  5. Dobson D. E., Kambe A., Block E., Dion T., Lu H., Castellot J. J., Jr, Spiegelman B. M. 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell. 1990 Apr 20;61(2):223–230. doi: 10.1016/0092-8674(90)90803-m. [DOI] [PubMed] [Google Scholar]
  6. Dunn B. E., Fitzharris T. P., Barnett B. D. Effects of varying chamber construction and embryo pre-incubation age on survival and growth of chick embryos in shell-less culture. Anat Rec. 1981 Jan;199(1):33–43. doi: 10.1002/ar.1091990105. [DOI] [PubMed] [Google Scholar]
  7. Folkman J., Langer R., Linhardt R. J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983 Aug 19;221(4612):719–725. doi: 10.1126/science.6192498. [DOI] [PubMed] [Google Scholar]
  8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  9. Gagliardi A., Collins D. C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993 Feb 1;53(3):533–535. [PubMed] [Google Scholar]
  10. Gospodarowicz D., Moran J., Braun D., Birdwell C. Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. Proc Natl Acad Sci U S A. 1976 Nov;73(11):4120–4124. doi: 10.1073/pnas.73.11.4120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289–322. doi: 10.1016/s1054-3589(08)60486-x. [DOI] [PubMed] [Google Scholar]
  12. Hayek A., Culler F. L., Beattie G. M., Lopez A. D., Cuevas P., Baird A. An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem Biophys Res Commun. 1987 Sep 15;147(2):876–880. doi: 10.1016/0006-291x(87)91011-4. [DOI] [PubMed] [Google Scholar]
  13. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991 Nov 15;51(22):6180–6184. [PubMed] [Google Scholar]
  14. Hélène C., Toulmé J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990 Jun 21;1049(2):99–125. doi: 10.1016/0167-4781(90)90031-v. [DOI] [PubMed] [Google Scholar]
  15. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990 Dec 6;348(6301):555–557. doi: 10.1038/348555a0. [DOI] [PubMed] [Google Scholar]
  16. Khan M. Y., Newman S. A. An assay for heparin by decrease in color yield (DECOY) of a protein-dye-binding reaction. Anal Biochem. 1990 May 15;187(1):124–128. doi: 10.1016/0003-2697(90)90428-c. [DOI] [PubMed] [Google Scholar]
  17. La Rocca R. V., Stein C. A., Danesi R., Myers C. E. Suramin, a novel antitumor compound. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):893–898. doi: 10.1016/0960-0760(90)90439-r. [DOI] [PubMed] [Google Scholar]
  18. Lee J. K., Choi B., Sobel R. A., Chiocca E. A., Martuza R. L. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg. 1990 Sep;73(3):429–435. doi: 10.3171/jns.1990.73.3.0429. [DOI] [PubMed] [Google Scholar]
  19. Maione T. E., Sharpe R. J. Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol Sci. 1990 Nov;11(11):457–461. doi: 10.1016/0165-6147(90)90127-t. [DOI] [PubMed] [Google Scholar]
  20. Maragoudakis M. E., Sarmonika M., Panoutsacopoulou M. Antiangiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system. J Pharmacol Exp Ther. 1989 Nov;251(2):679–682. [PubMed] [Google Scholar]
  21. Mignatti P., Rifkin D. B. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem. 1991 Nov;47(3):201–207. doi: 10.1002/jcb.240470303. [DOI] [PubMed] [Google Scholar]
  22. Moscatelli D., Quarto N. Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol. 1989 Nov;109(5):2519–2527. doi: 10.1083/jcb.109.5.2519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Myers C., Cooper M., Stein C., LaRocca R., Walther M. M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. doi: 10.1200/JCO.1992.10.6.881. [DOI] [PubMed] [Google Scholar]
  24. Nakamoto T., Chang C. S., Li A. K., Chodak G. W. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 1992 Feb 1;52(3):571–577. [PubMed] [Google Scholar]
  25. Pontzer C. H., Bazer F. W., Johnson H. M. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res. 1991 Oct 1;51(19):5304–5307. [PubMed] [Google Scholar]
  26. Proia A. D., Chandler D. B., Haynes W. L., Smith C. F., Suvarnamani C., Erkel F. H., Klintworth G. K. Quantitation of corneal neovascularization using computerized image analysis. Lab Invest. 1988 Apr;58(4):473–479. [PubMed] [Google Scholar]
  27. Risau W. Angiogenic growth factors. Prog Growth Factor Res. 1990;2(1):71–79. doi: 10.1016/0955-2235(90)90010-h. [DOI] [PubMed] [Google Scholar]
  28. Sato Y., Rifkin D. B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol. 1988 Sep;107(3):1199–1205. doi: 10.1083/jcb.107.3.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schiebinger R. J., Chrousos G. P., Cutler G. B., Jr, Loriaux D. L. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab. 1986 Jan;62(1):202–209. doi: 10.1210/jcem-62-1-202. [DOI] [PubMed] [Google Scholar]
  30. Schreiber A. B., Winkler M. E., Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science. 1986 Jun 6;232(4755):1250–1253. doi: 10.1126/science.2422759. [DOI] [PubMed] [Google Scholar]
  31. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. doi: 10.1200/JCO.1989.7.4.499. [DOI] [PubMed] [Google Scholar]
  32. Vu M. T., Smith C. F., Burger P. C., Klintworth G. K. An evaluation of methods to quantitate the chick chorioallantoic membrane assay in angiogenesis. Lab Invest. 1985 Oct;53(4):499–508. [PubMed] [Google Scholar]
  33. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1–8. doi: 10.1056/NEJM199101033240101. [DOI] [PubMed] [Google Scholar]
  34. Wilks J. W., Scott P. S., Vrba L. K., Cocuzza J. M. Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):73–77. doi: 10.1080/09553009114551581. [DOI] [PubMed] [Google Scholar]
  35. Wiseman D. M., Polverini P. J., Kamp D. W., Leibovich S. J. Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun. 1988 Dec 15;157(2):793–800. doi: 10.1016/s0006-291x(88)80319-x. [DOI] [PubMed] [Google Scholar]
  36. Woltering E. A., Barrie R., O'Dorisio T. M., Arce D., Ure T., Cramer A., Holmes D., Robertson J., Fassler J. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res. 1991 Mar;50(3):245–251. doi: 10.1016/0022-4804(91)90186-p. [DOI] [PubMed] [Google Scholar]
  37. Yayon A., Klagsbrun M. Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5346–5350. doi: 10.1073/pnas.87.14.5346. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES